CORTEVA ($CTVA) posted quarterly earnings results on Tuesday, November 4th. The company reported earnings of -$0.23 per share, beating estimates of -$0.54 by $0.31. The company also reported revenue of $2,618,000,000, beating estimates of $2,522,831,759 by $95,168,241.
You can see Quiver Quantitative's $CTVA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORTEVA Insider Trading Activity
CORTEVA insiders have traded $CTVA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CTVA stock by insiders over the last 6 months:
- CORNEL B FUERER (See Remarks) sold 55,242 shares for an estimated $3,759,770
- ROBERT D. KING (EVP, Crop Protection Business) sold 37,280 shares for an estimated $2,765,993
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CORTEVA Hedge Fund Activity
We have seen 642 institutional investors add shares of CORTEVA stock to their portfolio, and 557 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 6,140,710 shares (-87.6%) from their portfolio in Q3 2025, for an estimated $415,296,217
- HARRIS ASSOCIATES L P removed 6,043,980 shares (-46.7%) from their portfolio in Q2 2025, for an estimated $450,457,829
- FMR LLC added 4,777,344 shares (+52.8%) to their portfolio in Q2 2025, for an estimated $356,055,448
- CAPITAL WORLD INVESTORS added 3,934,636 shares (+20.4%) to their portfolio in Q2 2025, for an estimated $293,248,421
- VAN ECK ASSOCIATES CORP removed 3,775,701 shares (-43.9%) from their portfolio in Q2 2025, for an estimated $281,402,995
- INDEPENDENT FRANCHISE PARTNERS LLP removed 3,389,825 shares (-20.2%) from their portfolio in Q2 2025, for an estimated $252,643,657
- NUVEEN, LLC removed 2,409,731 shares (-23.7%) from their portfolio in Q2 2025, for an estimated $179,597,251
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORTEVA Analyst Ratings
Wall Street analysts have issued reports on $CTVA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 10/30/2025
- Wells Fargo issued a "Overweight" rating on 10/16/2025
- Argus Research issued a "Buy" rating on 10/13/2025
- BMO Capital issued a "Outperform" rating on 07/08/2025
- Jefferies issued a "Buy" rating on 06/06/2025
- Citigroup issued a "Buy" rating on 05/09/2025
- Morgan Stanley issued a "Overweight" rating on 05/09/2025
To track analyst ratings and price targets for CORTEVA, check out Quiver Quantitative's $CTVA forecast page.
CORTEVA Price Targets
Multiple analysts have issued price targets for $CTVA recently. We have seen 13 analysts offer price targets for $CTVA in the last 6 months, with a median target of $81.0.
Here are some recent targets:
- Joshua Spector from UBS set a target price of $81.0 on 10/30/2025
- Richard Garchitorena from Wells Fargo set a target price of $80.0 on 10/16/2025
- Alexandra Yates from Argus Research set a target price of $80.0 on 10/13/2025
- John Roberts from Mizuho set a target price of $78.0 on 10/08/2025
- Patrick Cunningham from Citigroup set a target price of $67.0 on 10/02/2025
- Jeffrey Zekauskas from JP Morgan set a target price of $70.0 on 10/02/2025
- Benjamin Theurer from Barclays set a target price of $84.0 on 08/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
